Saturday, 11th February 2017

Transcription

1 Friday, 10th February 2017 Opening Lecture Chairpersons: Karam Kostner and David Colquhoun Lipid Lowering Therapy: Exciting New Developments and Challenges 18:00-19:00 Peter Toth, University of Illinois College of Medicine, USA 19:00 Welcome Reception Saturday, 11th February :30-08:35 Opening Address: Karam Kostner Plenary Session 1 08:35-10:00 Hot Topics : Novel Lipid Lowering Therapies Chairpersons: Gerald Watts and Stephen Nicholls 08:35-09:00 PCSK9 Inhibitors: Is It all about LDL or Do They Have Pleiotropic Effects? Gilles Lambert, University of La Réunion, France 09:00-09:30 Recent Lipid Lowering Trials that will Change Clinical Practice Stephen Nicholls, University of Adelaide, Australia 09:30-10:00 Novel Lipid Lowering Therapies Gerald Watts, University of Western Australia, Australia 10:00-10:30 Coffee Break, Exhibition and E-poster Viewing

2 10:30-11:30 Workshop 1 Statin Intolerance Chairs: Patrick M. Moriarty and David Hare Definition of Statin Intolerance and Therapeutic Options Maciej Banach, Medical University of Lodz, Poland Role of PCSK9 Inhibitors Giuseppe Danilo Norata, University of Milan, Italy Workshop 2 Lipid Management in Diabesity and Chronic Renal Disease Chairs: Richard O Brien and John Prins How to treat Dyslipidemia of Diabesity Richard O Brien, University of Melbourne, Australia Risk Assessment in Diabetics- What Clinicians Need to Know Andrew Wilson, St Vincent s Hospital, Australia 11:30-13:00 11:30-12:00 12:00-12:30 12:30 13:00 13:00-14:00 14:00-15:00 Case Reports Maciej Banach, Medical University of Lodz, Poland; Patrick M. Moriarty, University of Kansas Medical Center USA; David Hare, University of Melbourne, Australia; Giuseppe Danilo Norata, University of Milan, Italy Plenary Session 2 Difficult to Treat Hyperlipidemia Chairpersons: Len Kritharides; Andrew Wilson Role of Ezetimibe Karam Kostner, University of Queensland, Australia Role of PCSK9-Inhibition Alberto Zambon, University of Padua, Italy Other Novel Therapies Peter Toth, University of Illinois College of Medicine, USA Workshop 3 Management of Paediatric Dyslipidemia Chairs: Robert Justo and Gary Leong When and How to Treat Dyslipidemia in Children Cases Robert Justo, University of Queensland, Brisbane, Australia LL Therapy in FH Children: When to start and which Agents? Shubha Srinivasan, The Children s Hospital, Australia All Cases: Robert Justo, University of Queensland, Brisbane, Australia; Gary Leong, University of Queensland, Australia; Shubha Srinivasan, How to Treat Dyslipidemia in Renal Disease Nicole Isbel, Princess Alexandra Hospital, Australia Satellite Lunch Symposium Redefining Clinical Lipid Lowering Practice in Post-ACS Patients. A Case-based Approach Chair: Karam Kostner Workshop 4 Nutraceuticals, Complementary Medicine and Diet to Treat Hyperlipidemia Chairs: Paul Nestel and David Colquhoun Dietary Fats: What is new? Paul Nestel, Baker IDI Heart & Diabetes Institute, Australia Which Neutraceuticals Work? David Colquhoun, University of Queensland, Australia Omega 3 Fatty Acids Trevor Mori, University of Western Australia, Australia

3 The Children s Hospital, Australia 15:00-15:30 Coffee Break, Exhibition and E-poster Viewing Plenary Session 3 15:30-17:00 Imaging of Atherosclerosis Chairpersons: Stephen Nicholls and Christian Hamilton-Craig Plaque Quantification and Atherosclerosis Regression 15:30 16:00 Stephen Nicholls, University of Adelaide, Australia Role of Coronary Calcium Scoring 16:00 16:30 Christian Hamilton-Craig, Cardiac Diagnostics Queensland, Australia Plaque Assessment in Clinical Practice 16:30 17:00 Warrick Bishop, Calvary Hospital, Australia

4 09:00-10:30 09:00 09:30 09:30 10:00 10:00-10:30 Plenary Session 4 Residual Risk: Lp(a)/HDL/TG Chairpersons: Maciej Banach and Gerhard M. Kostner Lp(a) - What the Clinician needs to know about Lp(a) Karam Kostner, University of Queensland, Australia When and How to Lower TG Anthony Keech, University of Sydney, Australia HDL: Risk Marker or Therapeutic Target? Philip Barter, University of New South Wales, Australia Role of Fribrates in 2017 Maciej Banach, Medical University of Lodz, Poland Sunday, 12th February :30-11:00 Coffee Break, Exhibition and E-poster Viewing Workshop 5 11:00-12:00 Lipid Management in General Practice Chairperson: Chrys Michaelides; Mark Nelsen Lipid Lowering Therapy in Elderly Patients Mark Nelson, University of Tasmania, Australia Workshop 6 Familial Hypercholesterolemia/Apheresis Chairpersons: Patrick M. Moriarty and Ian Hamilton-Craig Diagnosis and Therapy of FH Ian Hamilton-Craig, Griffith University, Australia 11:00 12:00 Can Genetic Testing and Imaging Help GPs? David Richards, Merridown Family Surgery, Australia Apheresis and other Therapies Patrick M. Moriarty, University of Kansas Medical Center, USA 12:00-13:00 12:00 13:00 Lipid Management in Remote Patients Rohan Corpus, State Coordinator at Queensland Health, Australia Plenary Session 5 Global Initiatives and Genetics Chairpersons: David Sullivan; David Colquhoun What did we learn from Genetics and who do we test? David Sullivan, University of Sydney, Australia Global Initiatives to Reduce The Burden of Disease: Need to Focus on Lipids David Colquhoun, University of Queensland, Australia

5 13:00-14:00 14:00-15:00 Workshop 7 Patient Advocacy and Registries Chairpersons: Gerald Watts; J. Redfern Why are Registries important and how do they work? Gerald Watts, University of Western Australia, Australia Satellite Symposium Where and when to use PCSK9 inhibitor, Alberto Zambon, University of Padua, Italy Chair: Karam Kostner Workshop 8 Hyperlipidemia in Various Conditions Patients: Who and How to Treat Chairpersons: Stan Woodhouse; Michael D Emden Stroke and LL Therapy David Colquhoun, University of Queensland, Australia Engaging the Patients in the Age of Social Media Julie Redfern, University of Sydney, Australia Dyslipidemia in HIV Patients A. Redmond LL Therapy in Diabetes Michael D Emden, Royal Brisbane and Women's Hospital, Australia LL Fatty Liver Disease Marno Ryan, St Vincent s Hospital, Melbourne, Australia 15:00 16:00 Abstract Session Low Levels of High-density Lipoprotein Cholesterol do not Predict the Incidence of Type 2 Diabetes in an Iranian High-risk Population: The Isfahan Diabetes Prevention Study Mohsen Janghorbani, Iran Current Dietary Guideline Advisory about Fat; Fact or De Facto Sam Mirzaee, Australia Benefits of L-thyroxine Replacement Therapy on Non-alcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients Lu Liu, China Vascular Health Promotion Program and Lipids Management in China Hongyu Wang, China Indentifying families with Familial Hypercholesterolemia to prevent deaths due to premature Coronary Artery Disease in India Jitendrapal Singh Sawhney, India The Impact Of Weight-Loss In Obese Patients On Serum Lipids In The Recent Randomised Weight-Loss Cvd Endpoint Trials Matthew Laraghy, Australia The First Successful Direct Adsorption of Lipoproteins (DALI) Apheresis during pregnancy in an Omani Woman Suffering from Homozygous Familial Hypercholesterolemia Suad Al-Mukhani, Oman Lipid Metabolism In Workers Occupationally Exposed To Mercury Vapour Anna Skoczynska, Poland Toddlers With Hypercholesterolaemia - Management Challenges

6 Shubha Srinivasan, Australia Children With Homozygous Familial Hypercholesterolemia (FH) On Lipoprotein Apheresis A 3 Year Follow Up Christina Taylan, Germany Idiopathic Ductopaenia In A Paediatric Patient: A Case Report And Interesting Clinical Biochemistry Louise Conwell, Australia Antioxidant Property Of Hdl And Cholesterol Efflux Capacity Are Mutually Independent Risk Markers For Atherosclerotic Cardiovascular Disease In Patients With Familial Hypercholesterolemia Masatsune Ogura, Japan Incidence Of Elevated Lipoprotein(A) Levels In A Very Large Community With Cardiac Disease Frank van Buuren, Germany Benefit Of The PCSK9 Inhibitor Evolocumab In Patients Undergoing Lipid Apheresis Frank van Buuren, Germany Investigation of Effect of Variant rs Associated With SORT1 on LDL Subfractions and Severity of Coronary Artery Disease Hüseyin Avni Uydu, Turkey The Triglyceride/High-density Lipoprotein Cholesterol Ratio Associates with Vulnerable Plaque Features on FD-OCT Imaging in Diabetic Patients Receiving a Statin Kohei Takata, Australia Association of Large HDL Particles Concentrations with Favorable HDL Functionality in Adolescents Kohei Takata, Australia Recent Lp(a) Apheresis Trial Patrick M. Moriarty, University of Kansas Medical Center, USA Prolongation of Pregnancy by Heparin-mediated extracorpor eal LDL-precipitation (H.E.L.P) Apheresis gains Fetal Weight in Preeclampsia, but does not lower soluble FMS-like tyrosine kinase-1 (sflt-1): The Freiburg Preeclampsia HELP-Apheresis Study M.Jansen 16:00-16:30 Closing Remarks Karam Kostner